新辅助免疫疗法联合化疗治疗食管癌的临床效果及短期预后分析  

Analysis on the Clinical Effect and Short-Term Prognosis of Neoadjuvant Immunotherapy Combined with Chemotherapy in the Treatment of Esophageal Cancer

作　　者：何厚乐 邢亚闯 刘杰 罗俊辉 Houle;XING Yachuang;LIU Jie;LUO Junhui(Department of Cardiothoracic Surgery,the 989h Hospital of Joint Logistics Support Force of the Chinese People's Liberation Army,Luoyang 471031,China)

机构地区：[1]中国人民解放军联勤保障部队第九八九医院心胸外科,河南洛阳471031

出　　处：《临床医学工程》2024年第12期1487-1488,共2页Clinical Medicine & Engineering

摘　　要：目的分析新辅助免疫疗法联合化疗治疗食管癌患者的临床效果及短期预后。方法68例食管癌患者随机分为两组。参照组接受手术治疗,研究组在参照组基础上接受新辅助免疫疗法联合化疗。比较两组的临床疗效、肿瘤标志物水平、复发率与生存率。结果研究组的ORR为58.82%,高于参照组的32.35%(P<0.05)。治疗后,研究组的血清CA125、CEA水平均低于参照组(P<0.05)。研究组的复发率低于参照组,生存率高于参照组(P<0.05)。结论新辅助免疫疗法联合化疗治疗食管癌可明显提升临床效果,降低患者的肿瘤标志物表达,改善患者的短期预后。Objective To analyze the clinical effect and short-term prognosis of neoadjuvant immunotherapy combined with chemotherapy in the treatment of patients with esophageal cancer.Methods A total of 68 patients with esophageal cancer were randomly divided into two groups.The reference group received surgical treatment,and the study group received neoadjuvant immunotherapy combined with chemotherapy on the basis of the reference group.The clinical efficacy,tumor marker levels,recurrence rate and survival rate were compared between the two groups.Results The ORR of the study group was 58.82%,higher than 32.35%of the reference group(P<0.05).After treatment,the levels of serum CA125 and CEA of the study group were lower than those of the reference group(P<0.05).The recurrence rate of the study group was lower than that of the reference group,and the survival rate was higher than that of the reference group(P<0.05).Conclusions Neoadjuvant immunotherapy combined with chemotherapy in the treatment of esophageal cancer can significantly improve the clinical efficacy,reduce the expressions of tumor markers,and improve the short-term prognosis of patients.

关 键 词：食管癌 新辅助免疫疗法 化疗 临床疗效 短期预后 

分 类 号：R735.1[医药卫生—肿瘤]